Abstract
The outcome of radioiodine therapy of Graves’ hyperthyroidism was retrospectively evaluated in 274 consecutive patients treated from 1975 to 1984. At 1-yr follow-up, permanent hypothyroidism occurred in 36.9% of patients and the cumulative incidence of hypothyroidism progressively increased up to 79.3% after 7–10 yr. At the end of the follow-up period, 148 patients (54%) were hypothyroid, 115 (42%) euthyroid and 11 (4%) still hyperthyroid. The prevalence of hypothyroidism was significantly higher in patients with small goiters (≤ 50 g) than in those with large goiters (> 90 g). Moreover, hypothyroidism was more frequent in patients with high thyroglobulin antibodies titers (≥ 1: 25,600) than in those with low titers or negative tests, and occurred earlier in the former group than in the latter ones Correction of thyrotoxicosis was obtained after the administration of a single dose of 131I in 187 patients (63.6%); 69 patients required two doses and 11 three or more doses. Seven patients refused further treatment with 131I after the first dose. In an effort to identify possible factors affecting the efficacy of 131I therapy, we avaluated the results obtained after the administration of the first dose of radioiodine. We found that large goiters, rapid iodide turnover and adjunctive therapy with methimazole shortly after radioiodine were associated with a higher rate of persistence of thyrotoxicosis, whereas an increased prevalence of hypothyroidism was observed in patients with small goiters and in those not treated with methimazole up to one week after 131I. On the other hand pretreatment with methimazole before radioiodine administration did not affect the outcome of treatment. Thus, if correction of thyrotoxicosis, irrespective of the occurrence of hypothyroidism, has to represent the goal of radioiodine therapy of Graves’ disease, the following points should be kept in mind: i) Large goiters and goiters with a rapid iodine turnover should receive larger 131I doses/g thyroid tissue; ii) Methimazole should not be given shortly after radioiodine: if thyrotoxicosis is severe, the antithyroid drugs may be given prior to 131I therapy to restore euthyroidism, without limiting the efficacy of radiodiodine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blomfield G.W., Eckert H., Fisher M., Miller MA, Munro D.S., Wilson G.M. Treatment of thyrotoxicosis with 131I. Br. Med. J. 7: 63, 1959.
Nofal M.M., Beyerwaltes W.H., Patno M.E. Treatment of hyperthyroidism with sodium iodide 131I. A 16-year experience. JAMA 797: 605, 1966.
Tunbridge W.M.G., Harsoulis P., Goolden A.W. Thyroid function in patients treated with radioactive iodine for thyroroxicosis. Br. Med. J. 3: 89, 1974.
Beierwaltes W.H. The treatment of hyperthyroidism with iodine-131. Semin. Nucl. Med. 6: 95, 1978.
Beker D.W. Current status of radioactive iodine treatment of hyperthyroidism. Thyroid Today 2: 1, 1979.
Goolden A.W.G., Stewart J.S.W. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin. Endocrinol (Oxf.) 24: 217, 1986.
Cunnien A.J., Hay I.D., Gorman CA., Offord K.P., Scanion P.W. Radioiodine induced hypothyroidism in Graves’ disease: factors associated with the increasing incidence. J. Nucl. Med. 23: 978, 1982.
Sridama V., McCormick M., Kaplan E.L., Fauchet R., DeGroot L.J. Long-term follow-up study of compensated low-dose 131I therapy for Graves’ disease. N. Engl. J. Med. 311: 426, 1984.
Glennon J.A., Gordon E.S., Sawin C.T. Hypothyroidism after low-dose 131 treatment of hyperthyroidism. Ann. Intern. Med. 76: 721, 1972.
Latapie J.L., Lefort G., Commenges M., Roger P., Riviere L.J., Mauriac L. Traitement de la maladie de Basedow par petites doses répétées d’iode 131. Ann. Endocrinol. 47: 601, 1980.
Viherkoski M., Lamberg B.A., Henberg CA., Niemi E. Treatment of toxic nodular and diffuse goiter with radioactive iodine. Acta Endocrinol. (Copenh.) 64: 159, 1970.
Steinbach J.J., Donoghue G.D., Goldman J.K. Simultaneous treatment of toxic diffuse goiter with 1-131 and antithyroid drugs: a prospective study. J. Nucl. Med. 20: 1263, 1979.
Bliddal H., Hansen J.N., Rogowski P., Johansen K., Friis T., Siersbaek-Nielsen 131I treatment of diffuse and nodular toxic goiter with or without antithyroid agents. Acta Endocrinol. (Copenh.) 99: 517, 1982.
Velkeniers B., Cytryn R., Vanhaelst L., Jonckeer M.H. Treatment of hyperthyroidism with radioiodine: adjunctive therapy with antithyroid drugs reconsidered. Lancet 2: 1127, 1988.
Refetoff S., Demeester-Mirkine N., Hermans A.M., DeGroot L.J. Rapid control of thyrotoxicosis with combined 131I, antithyroid drugs and Kl therapy. J. Nucl. Med. All. Sci. 27: 23, 1977.
Green M., Wilson G.M. Thyrotoxicosis treated by surgery, or iodine-131. With special reference to development of hypothyroidism. Br. Med. J. 7: 1005, 1964.
Lundell G., Jonsson J. Thyroid antibodies and hypothyroidism in 131 therapy for hyperthyroidism. Acta Radiol. 12: 443, 1973.
Lundell G.L., Holm E.J. Hypothyroidism following 131I therapy for hyperthyroidism in relation to immunological parameters. Acta Radiol. Oncology 19: 449, 1981.
Goolden A.W.G., Russel Fraser T. Effect of pretreatment with Carbimazole in patients with thyrotoxicosis subsequently treated with radioactive iodine. Br. Med. J. 3: 443, 1969.
Van Hofe S.E., Dorfman S.G., Carretta R.F., Young R.L. The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter. J. Nucl. Med. 79: 180, 1978.
Reynolds L.R., Kotchen T.A. Antithyroid drugs and radioactive iodine. Fifteen years’ experience with Graves’ disease. Arch. Intern. Med. 739: 651, 1979.
Sawers J.S.A., Toft A.D., Irvine W.J., Brown N.S., Seth J. Transient hypothyroidism after iodine-131 treatment of thyrotoxicosis. J. Clin. Endocrinol. Metab. 50: 226, 1980.
Peto R., Pike M.C., Harmitage P., Berslow N.E., Cox D.R., Howard S.V., Mantel N., McFerson K., Peto J., Smith P.G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br. J. Cancer 35: 1, 1977.
Studer H., Huber G., Derwahl M., Frey P. Die Umwandlung von Basedowstrumen in Knotenk-ropfe: ein Grund des Hyperthyreoserezidivs. Schweiz Med. Wschr. 119: 203, 1989.
Doniach D. Humoral and genetic aspects of thyroid autoimmunity. Clin. Endocrinol. Metab. 4: 267, 1975.
Pinchera A., Liberti P., Martino E., Fenzi G.F., Grasso L., Rovis L., Baschieri L., Doha G. Effect of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. J. Clin Endocrinol. Metab. 29: 231, 1969.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marcocci, C., Gianchecchi, D., Masini, I. et al. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves’ hyperthyroidism. J Endocrinol Invest 13, 513–520 (1990). https://doi.org/10.1007/BF03348615
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348615